MoonLake Immunotherapeut... Stock Quote MLTX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

44.77

Bid

42.00

Ask

47.00

Volume

84,491

44.48 Day's Range 45.72

35.11 52 Week Range 64.98

Market Cap

2.859B

Previous Close

44.91

Open

45.19

Last Trade

Last Trade Time

Financial Volume

$ 3,792,351

VWAP

44.8847

Average Volume (3m)

354,641

Shares Outstanding

63,869,904

Dividend Yield

PE Ratio

-65.15

Earnings Per Share (EPS)

-0.69

Revenue

Net Profit

-44.08M

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Sector

Blank Checks

Industry

Pharmaceutical Preparations

Website

moonlaketx.com

Headquarters

Grand Cayman, Cym

Founded

2020

MoonLake Immunotherapeutics is listed in the Blank Checks sector of the NASDAQ with ticker MLTX. The last closing price for MoonLake Immunotherapeut... was $44.91. Over the last year, MoonLake Immunotherapeut... shares have traded in a share price range of $ 35.11 to $ 64.98.

MoonLake Immunotherapeut... currently has 63,869,904 shares outstanding. The market capitalization of MoonLake Immunotherapeut... is $2.87 billion. MoonLake Immunotherapeut... has a price to earnings ratio (PE ratio) of -65.15.

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis Builds upon the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa VELA is the first Phase 3 program in hidradenitis...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.155	-0.345019476906	44.925	47.17	44.09	331149	45.24059327	CS
4	2.64	6.26631853786	42.13	50.53	39.91	432313	45.10314992	CS
12	1.26	2.89588600322	43.51	50.53	37.55	354641	42.65082007	CS
26	-12.09	-21.2627506155	56.86	64.98	37.55	414347	47.20045646	CS
52	-11.48	-20.4088888889	56.25	64.98	35.11	500559	49.96003426	CS
156	32.4	261.924009701	12.37	64.98	4.25	356451	42.03109442	CS
260	32.4	261.924009701	12.37	64.98	4.25	356451	42.03109442	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M